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Background: Peginterferon alfa and ribavirin combination therapy is an effective treatment for many patients with chronic hepatitis C virus (HCV). Reducing the length of treatment may be
advantageous. We performed a systematic review and economic evaluation to assess shorter treatment duration of this regimen.
Methods: We searched fourteen bibliographic databases (including The Cochrane Library, Medline, and Embase) from 2000 to October 2009 and consulted experts and drug manufacturers. Eligible
articles were randomized controlled trials (RCTs) selected according to predefined criteria. We undertook an economic evaluation to assess the cost-effectiveness of shortened treatment versus
standard treatment in the UK.
Results: Six trials were included. In the sub-group of patients who had low viral load (LVL) and a rapid virological response (RVR), there were no statistically significant differences in sustained
virological response (SVR) rates between patients who received standard treatment (range, 83 percent to 100 percent) and those who received shortened courses (range 84 percent to 96 percent)
(24 weeks for genotype 1, 16 weeks for genotype 2/3). Shortened treatment resulted in cost savings, but in some scenarios also resulted in poorer outcome, compared with standard treatment.
This requires a judgment to be made on the value of the quality-adjusted life-year loss resulting from adopting a shorter treatment regimen, if shorter treatment is associated with a lower SVR than
standard treatment duration.
Conclusions: For chronic HCV patients who have LVL and achieve an RVR, shortened peginterferon and ribavirin combination therapy could be considered as a viable treatment option.
Keywords: Chronic hepatitis C, Cost-effectiveness, Economic evaluation, Peginterferon alfa, Systematic review
Infection with hepatitis C virus (HCV) is a significant pub-
lic health problem. The estimated global prevalence of chronic
HCV is around 2–3 percent, corresponding to approximately
130–170 million people (23;24). Peginterferon alfa and rib-
avirin combination therapy is currently the standard treatment
for chronic HCV in a number of countries (4;7;15;16). Success-
ful treatment is considered to be attainment of a sustained vi-
rological response (SVR), defined as undetectable serum HCV
RNA 6 months after cessation of treatment. In recent years, one
of the key aims of the management of HCV is to maximize
the likelihood of an SVR while minimizing potential adverse
effects of treatment. The adverse effects associated with inter-
feron based anti-viral treatment (e.g., flu-like symptoms, nau-
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sea, vomiting, depression) and ribavirin (e.g., anemia) can be
significant, and some patients describe it as a very unpleasant
experience, disrupting their social and family life, and in some
cases impairing their ability to work. Extensions to the original
licenses for the two available peginterferons (α-2a and α-2b) al-
low patients who have a low viral load (LVL) and achieve a rapid
virological response (RVR) (negative qualitative HCV RNA) at
4 weeks treatment to receive shortened treatment courses. Spar-
ing patients the potential adverse effects through shorter, effec-
tive treatment courses will make therapy more tolerable, and
may have the additional advantage of encouraging more people
with suspected HCV to present for diagnosis, assessment and
treatment. It may also be a cost-effective option, although this
requires further empirical investigation.
We assessed the clinical and cost-effectiveness of peginter-
feron alfa and ribavirin for the treatment of chronic HCV in
patients eligible for shortened treatment to help inform UK pol-
icy recommendations (18). It is part of a larger review evaluating
treatment in several patient sub-groups affected by the license
extensions (8) and also further updates and extends our previ-
ously published research into the clinical and cost-effectiveness
of treatments for chronic HCV (9;19).
METHODS
A sensitive literature search was applied to fourteen elec-
tronic bibliographic databases (includingTheCochraneLibrary,
398
Shortened treatment for chronic hepatitis C
Medline and Embase) from 2000 to October 2009. Key hepatitis
C resources and symposia, bibliographies, and industry submis-
sions were also searched and clinical experts were contacted.
Randomized controlled trials (RCTs) of adults with chronic
HCVwho were eligible for shortened treatment (i.e., with base-
line LVL and an RVR at week 4 of treatment) were included.
Studies had to evaluate standard peginterferon alfa and ribavirin
combination therapy (or monotherapy for those unable to tol-
erate ribavirin) compared with shortened duration courses of
combination therapy (24 weeks for genotype 1; 16 weeks for
genotype 2/3, as per the licenses). Outcomes included measures
of virological response (RVR and SVR), relapse rate, and ad-
verse events. In addition, full economic evaluations and studies
of health-related quality of life (HRQoL) were sought for this
sub-group of patients.
Inclusion criteria were applied, data were extracted and
quality was assessed by two reviewers independently, with any
differences in opinion resolved through discussion. Method-
ological quality was evaluated using standard criteria (2) and the
risk of bias was assessed following the principles of Cochrane
methodology (10). Data were synthesized through a narrative
review. A meta-analysis was not undertaken due to differences
in the drug regimens, and because outcome data were based on
relatively small sub-groups of the randomized patients. Further
details on the search strategy and the systematic methods used
to inform the review are presented in the full research report
(8).
Description of the Model
A published Markov model (20) was adapted to estimate the
cost-effectiveness of a shortened course of peginterferon α-
2a or peginterferon α-2b combination therapy, compared with
standard duration of treatment, for the treatment of chronic
HCV in eligible patients. The model had a lifetime horizon and
a cycle length of 1 year, with a half-cycle correction applied.
The perspective was that of the UK National Health Service
(NHS) and personal and social services (PSS), and a discount
rate of 3.5 percent was applied to both future costs and benefits.
Patients have a mean age at entry to the model of 40, and
70 percent of the cohort is male (6;14). The distribution of
patients across stages of liver disease was taken from a clinical
audit of patients at a liver unit (6): 46 percent of these had mild
disease, 44 percent moderate disease, and 10 percent cirrhosis.
SVR estimates for patients receiving shortened courses of
treatment were taken from trials included in our systematic re-
view of clinical effectiveness. Transition probabilities for pro-
gressive liver disease were based on data reported in an RCT
of treatment of patients with mild hepatitis C (26) (for progres-
sion from mild to moderate liver disease, and from moderate
disease to compensated cirrhosis), from the literature on natu-
ral history and previous economic evaluations (further details
are presented in the full research report [8]). Patients with mild
or moderate liver disease, or compensated cirrhosis, faced the
same mortality risk as the general population, whereas patients
with more severe disease faced higher mortality rates, related
to their stage of liver disease (8).
Health state utilities for patients with chronic HCV and
associated liver disease, assessed using the EuroQol-5D in
the mild hepatitis C RCT (26) and valued using a gen-
eral population tariff (5), were applied in the model (see
Supplementary Table 1, which can be viewed online at
www.journals.cambridge.org/thc2012049) (20). Utilities were
reduced during the year in which treatment occurred to take
account of the adverse effect of anti-viral treatment on HRQoL.
Drug unit costs were taken from the British National For-
mulary (September 2009). For patients receiving peginterferon
α-2a and ribavirin therapy, the total drug costs estimated in
genotype 1 patients were GBP5,712 and GBP11,425 for 24
weeks and 48weeks treatment respectively. For genotype 2/3 pa-
tients receiving this drug combination, the cost was GBP3,216
for 16 weeks and GBP4,824 for 24 weeks. For patients receiv-
ing peginterferon α-2b and ribavirin, the total drug costs were
GBP5,540 for 24 weeks and GBP11,081 for 48 weeks of treat-
ment (genotype 1 only).
Costs of monitoring and additional patient management
while on anti-viral treatment were based on those used in our
previous economic evaluation (20). Health state costs for SVR,
chronic HCV, compensated cirrhosis, decompensated cirrhosis,
and hepatocellular carcinoma have been taken from an obser-
vational study conducted alongside the mild hepatitis C RCT
(26), and are reported in Supplementary Table 2, which can
be viewed online at www.journals.cambridge.org/thc2012050.
Liver transplantation costs were taken from aUKDepartment of
Health funded study (12). The base year for costs in the analysis
is 2007/8 (3).
Deterministic base case results, in terms of total and incre-
mental costs and quality-adjusted life-years (QALYs) for each
strategy, and incremental cost per QALY gained, are reported.
Due to difficulties in interpreting incremental cost-effectiveness
ratios (ICERs) and applying standard cost-effectiveness de-
cision rules where interventions are cost-saving and QALY-
reducing (see Supplementary Appendix, which can be viewed
online at www.journals.cambridge.org/thc2012051), we also
report results in terms of incremental net monetary benefits
(INMB) (21;22).
Evaluation of Uncertainty
Univariate sensitivity analysis was used to address particular ar-
eas of uncertainty in the model related to structure and method-
ological assumptions as well as transition probabilities around
which there is considerable uncertainty.
Parameter uncertainty was addressed using probabilistic
sensitivity analysis (PSA). The probability of achieving SVR,
health state costs, health state utility values, and transition prob-
abilities for the natural history parameters were sampled using
probability distributions assigned to the point estimates used in
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2706 records identified through 
database searching 
78 additional records identified 
through other sources* 
2400 records after duplicates removed 
2400 records screened 2310 records excluded 
90 full-text articles assessed 
for eligibility 
6 RCTs reported in 8 
publications included in 
qualitative synthesis  
82 full-text articles 
excluded, with reasons 
Study design = 26 
Population = 28 
Intervention = 27 
Outcomes = 1 
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analysis) 
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Figure 1. Prisma flow chart. The asterisk indicates key hepatitis C symposia, conference abstracts, and bibliographies. RCTs, randomized controlled trials.
the base case analysis. Characteristics of the distributions used
for sampling are reported in full elsewhere (8).
RESULTS
Quantity and Quality of Research
After screening (Figure 1), six RCTs were included
(1;11;13;25;27;28). Shortened treatment in patients with geno-
type 1 was evaluated in four trials (1;11;13;27), genotype 2 in
one trial (28), and genotype 2/3 in one trial (25). In five of
the trials, patients had LVL (<400,000 IU/ml (27) or ≤800,000
IU/ml (1;11;25;28)) at baseline (based on mean viral load). In
the sixth trial (Mangia and colleagues (13), only 24 percent of
patients had LVL at baseline (<400,000 IU/ml), but the trial
was included because results were reported for the sub-group
of patients with an LVL and RVR. A comparison of baseline
characteristics of the RVR/LVL subgroups was not presented
by the trials, although within studies the main treatment groups
were similar at baseline on demographic, biochemical, and vi-
rological characteristics. Methodological reporting and qual-
ity varied between the included studies, although quality was
judged to be good overall. The possibility of detection bias
was deemed minimal as the objective “hard” end point of SVR
is unlikely to be influenced by a lack of blinding. However,
there may be a risk of selection bias in four trials where it
was unclear if there was adequate concealment of allocation
to treatment groups. Table 1 shows the primary outcome sum-
maries of the included trials. The key characteristics, method-
ological quality, and some secondary outcome measures can be
seen in Supplementary Table 3, which can be viewed online at
www.journals.cambridge.org/thc2012052.
CLINICAL EFFECTIVENESS RESULTS
Sustained Virological Response
In the sub-group of patients with LVL who attained an RVR,
SVR rates were comparable between groups who received the
standard duration of treatment (range, 83 percent to 100 percent)
and shortened courses (range 84 percent to 96 percent), with no
statistically significant differences between treatment arms. In
addition, SVRswere broadly similar regardless of genotypewith
the exception of one trial of genotype 1 patients where SVRs
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Table 1. Clinical Effectiveness: Primary Outcome and Adverse Events
Study details Group 1 Group 2 p value
Berg et al., 2009 (1)
Genotype 1
PEG α-2b + RBV
48wks (n = 225)
PEG α-2b + RBV
24wks (n = 28)
SVR by RVR and LVL (≤800,000 IU/ml)a
SVR by RVRb
Dose discontinuation for any AE
Serious adverse event
75% (3/4)
42% (8/19)
3%
6.6%
69% (11/16)
57% (16/28)
2%
2.6%
Not reported
Not reported
Not statistically tested
Not statistically tested
Mangia et al., 2008 (13)
Genotype 1
PEG α-2a or α-2b + RBV,
48wks (n = 237)
PEG α-2a or α-2b + RBV,
24wksc (n = 123)
SVR by RVR and LVL (<400,000 IU/ml)
Dose discontinuation for any AE
83.3% (20/24)
7%
84.4% (38/45)
Only reported for whole of variable
treatment group (not 24 wks group only)
p = 0.83
Not reported
Liu et al., 2008 (11)
Genotype 1
PEG α-2a + RBV
24 wks (n = 154)
PEG α-2a + RBV
48 wks (n = 154)
SVR by RVR and LVL (<400,000 IU/ml)
SVR by RVR and LVL (<800,000 IU/ml)
Dose discontinuation for any AE
Serious adverse event
Bodyweight loss (>10% reduction)
100% (42/42)
100% (57/57)
9%
3%
30%
94% (49/52)
94% (69/73)
4%
7%
19%
p = 0.25
p = 0.13
Not statistically tested
Not statistically tested
p = 0.03
Yu et al., 2008 (27)
Genotype 1
PEG α-2a + RBV
24 wks (n = 100)
PEG α-2a + RBV
48 wks (n = 100)
SVR by RVR and LVL (<400,000 IU/ml)
Dose discontinuation – total
– for any AE
– for other reason
Serious adverse event
100% (24/24)
10%
8%
2%
1%
96.4% (27/28)
3%
3%
0
1%
p = 1.000, difference
−3.6% (95% CI
−14.3% to -0.6%)
p = 0.045
Not statistically tested
Not statistically tested
Not statistically tested
Yu et al., 2007 (28)
Genotype 2
PEG α-2a + RBV
24 wks (n = 100)
PEG α-2a + RBV
16 wks (n = 50)
SVR by RVRd
Dose discontinuation – total
– for any AE
Serious adverse event
Alopecia
98% (85/87)
1%
1%
0
49%
100% (43/43)
0
0
0
20%
p = 1
Not statistically tested
Not statistically tested
Not statistically tested
p = 0.001
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Table 1. Continued.
Study details Group 1 Group 2 p value
von Wagner et al., 2005 (25)
Genotype 2 or 3
PEG α-2a + RBV
16 wks (n = 71)
PEG α-2a + RBV
24 wks (RVR) (n = 71)
SVR by RVR and LVL (≤800,000 IU/ml)
Dose discontinuation – total
– for any AE
– for other reason
87% (27/31)
8%
1%
7%
94% (33/35)
1%
1%
0
p = not reported
Not statistically tested
Not statistically tested
Not statistically tested
Note. Values are % (n/N) unless otherwise stated.
aLVL threshold outside the licence (<600,000 IU/ml)(26) therefore SVR by RVR presented also since mean baseline viral load was low (∼500,000 IU/ml).
bSub-group who first became HCV RNA negative at, but not before, week 4 only.
cn = 459, treatment duration based on time when HCV RNA first became undetectable. Patients who were first HCV RNA-negative at week 4, 8, or 12 were treated for
24 (n = 123), 48 or 72 weeks, respectively.
dSVR by RVR and LVL not reported; assume rates similar to SVR by RVR since mean baseline viral load was low and approximately 83% had LVL at baseline.
eAll treated for 8 weeks and those with RVR at week 4 were randomized to a further 8 or 16 weeks treatment (giving a total treatment of 16 or 24 weeks, respectively),
patients without RVR not reported here.
AE, adverse event; LVL, low viral load; PEG, peginterferon; RBV, ribavirin; RVR, rapid virological response; SVR, sustained virological response; wks, weeks.
were noticeably lower for standard compared with shortened
treatment (42 percent versus 57 percent, respectively) (1). This
may be a consequence of the study design where the SVR rates
presented are for those patients who first became HCV RNA-
negative at week 4 and do not include those who also became
negative during weeks 1 to 3 as in the other trials. It should
also be noted that patient numbers in the LVL/RVR sub-groups
were relatively small and none of the trials were powered for
this sub-group analysis.
Rapid Virological Response
For both genotype 1 and genotype 2/3 patients, rates of RVR
were observed to be similar between groups who received stan-
dard treatment (range, 26 percent to 63 percent) versus those
who received shortened courses (range, 27 percent to 68 per-
cent) (not statistically significant in two trials; not statistically
tested in four trials). There was a large range in reported RVR
rates between the studies, but the proportion of patients achiev-
ing an RVR was generally higher in those with genotype 2/3
than in those with genotype 1. The low RVR rates in the trial by
Mangia and colleagues (13) may be due to the smaller propor-
tion of patients (24 percent) having LVL at baseline.
Relapse Rate
In the one trial (27) reporting virological relapse rates in the
LVL/RVR sub-group, rates were low and not statistically signif-
icantly different between those treated for 24 versus 48 weeks
(3.6 percent versus 0, respectively, difference 3.6 percent (95
percent confidence interval, -7.2 percent to 6.6 percent), p =
1.000).
Adverse Events
Adverse events were reported for treatment groups as a whole,
and the reporting of statistical tests by the trials varied. The
most frequently occurring adverse events were similar across all
the trials and included flu-like symptoms, insomnia, anorexia,
dermatological symptoms, and alopecia. On the whole, the fre-
quency of adverse events were not statistically different between
treatment arms (where reported), although there was a trend for
a lower incidence of adverse events and fewer dose discontinu-
ations in patients receiving a shortened treatment regimen.
RESULTS OF ECONOMIC EVALUATION
Costs and outcomes modelled for patients eligible for shortened
duration of treatment with peginterferon and ribavirin combi-
nation therapy are presented in Table 2. Separate analyses are
presented for each trial included in the systematic review of clin-
ical effectiveness, as meta-analysis of RCTs was not considered
appropriate (discussed earlier).
Peginterferon α-2a
For genotype 1 patients, shortened duration (24 weeks) of treat-
ment is associated with a reduction in total costs between ap-
proximately GBP4,800 and GBP5,200. While the small re-
duction in SVR associated with shortened treatment duration
results in some additional costs from disease progression for
this cohort, these are not sufficient to offset the cost reduction
arising from the shorter duration of treatment. The reduction in
treatment-related adverse events expected for shorter duration
of treatment does not fully offset the reduction in QALYs due
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Table 2. Base Case Cost-Effectiveness for Shortened Treatment Duration Using Peginterferon (α-2a or α-2b) and Ribavirin Combination Therapy
Standard treatment
Shortened
treatment Incremental INMB (GBP)
Patient group and Cost Outcome Cost Outcome Cost Outcome ICER (GBP per λ = λ =
RCT treatment length (GBP) (QALYs) (GBP) (QALYs) (GBP) (QALYs) QALY gained) 20,000 30,000
Peginterferon α-2a and ribavirin
Liu et al, 2008 (11) Genotype 1 14,206 15.68 9,399 15.54 −4,807 −0.14 34,510 2,021 628
48 weeks vs. 24 weeks
Yu et al., 2008 (27) Genotype 1 14,206 15.68 8,994 15.60 −5,212 −0.08 64,880 3,605 2,802
48 weeks vs. 24 weeks
Yu et al., 2007 (28) Genotype 2 7,834 15.64 5,728 15.72 −2,107 0.08 Shortened duration dominates 3,727 4,537
24 weeks vs. 16 weeks
von Wagner et al., 2005 (25) Genotype 2 or 3 10,089 15.31 6,943 15.54 −3,146 0.23 Shortened duration dominates 7,788 10,109
24 weeks vs. 16 weeks
Peginterferon α-2b and ribavirin
Berg et al., 2009 (1) Genotype 1 26,169 19.74 17,173 20.03 −8,996 0.29 Shortened duration dominates 18,888 23,833
48 weeks vs. 24 weeks
GBP, Great Britain pounds; ICER, incremental cost-effectiveness ratio; INMB, incremental net monetary benefits; RCT, randomized controlled trial; QALY, quality-adjusted life-year.
to a larger proportion of patients experiencing progressive liver
disease in the cohort of patients receiving shortened duration
of treatment. Hence, shortened treatment duration is associ-
ated with an overall QALY loss (between 0.08 and 0.14). The
ICERs range from GBP34,150 to GBP64,880. Given that both
incremental costs and QALYs are negative, the conventional
cost-effectiveness decision rule (where a technology should be
adopted if the ICER is below a given threshold value) does not
apply (see Supplementary Appendix). The INMB are positive,
indicating that shortened duration of treatment with peginter-
feron α-2a combination therapy is a cost-effective option for
genotype 1 patients with LVL at baseline and who achieve RVR.
For patients with genotype 2 or 3 receiving the shortened
course, there was a reduction in total costs of between approx-
imately GBP2,100 and GBP3,150. The higher SVR for the
shorter duration of treatment also results in a gain in total
QALYs of between 0.08 and 0.23, which leads to shortened
treatment dominating standard duration treatment.
Peginterferon α-2b
Shorter duration of treatment was associated with a reduction in
total costs of approximately GBP9,000. There were also small
reductions in total costs associatedwith a reduced risk of disease
progression in this cohort. In addition, there was a QALY gain
of 0.49 due to a higher SVR in shortened treatment duration, so
this strategy dominated standard treatment.
Deterministic Sensitivity Analysis
A deterministic sensitivity analysis (DSA) was undertaken,
which consisted predominantly of univariate sensitivity anal-
yses, where one parameter is varied at a time. These analyses
encompassed structural uncertainties in the model, uncertain-
ties over the composition of the baseline cohort and uncertainty
over parameter values. The DSA suggested that the results in
peginterferon α-2a for all genotypes, and peginterferon α-2b
for genotype 1 were generally robust to changes in structural
assumptions and input parameter values. Reducing drug acqui-
sition costs has the effect of reducing the cost-effectiveness of
shortened treatment duration, as it reduces the cost saving be-
tween standard and shortened treatment duration while the out-
come difference is unchanged. Incremental costs and QALYs
were most sensitive to changes in assumptions regarding the
baseline characteristics of the patient cohort. In particular, the
cost-effectiveness estimates were highly sensitive to the mean
starting age and stage of liver disease. The sensitivity analysis
suggested that shortened treatment duration was most likely to
be cost-effective in older patients and thosewith less severe liver
disease associated with chronic HCV infection. Full results of
the DSA are reported elsewhere (8).
Given that some included trials reported potentially counter-
intuitive results (with shortened treatment duration being
more effective, in terms of SVR, than standard duration) we
conducted an additional scenario analysis on the impact of
the difference in SVR on the cost-effectiveness results, as-
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suming that the SVR for shortened treatment duration is
less than or equal to that for standard treatment duration
(see Supplementary Table 4, which can be viewed online
at www.journals.cambridge.org/thc2012053). This suggested
that,where the difference in SVRwas small (less than 2 percent),
shortened treatment duration may be a highly cost-effective op-
tion, particularly for genotype 1 patients. However, as the SVR
difference increases, the potential cost savings reduce, and the
QALY loss increases rapidly, particularly for genotype 2 or 3
patients.
Probabilistic Sensitivity Analysis
For genotype 1 patients shortened treatment duration using
peginterferon α-2a combination therapy had a probability of
being cost-effective of 83 percent at a willingness to pay thresh-
old of GBP20,000 per QALY and 59 percent at a willingness
to pay threshold of GBP30,000, using efficacy data from the
trial reported by Liu and colleagues (11). The equivalent values
using efficacy data from the trial reported by Yu and colleagues
(27) are 100 percent at both willingness to pay thresholds. For
genotypes 2 or 3 patients, the probability of shortened treat-
ment duration using peginterferon α-2a combination therapy
being cost-effective was 100 percent at both willingness to pay
thresholds using efficacy data from either included trial (25;28).
Similar results were observed for shortened treatment dura-
tion using peginterferon α-2b combination therapy in genotype
1 patients.
DISCUSSION
The clinical evidence in this systematic review consists of six
RCTs of reasonable methodological quality. The data suggest
that chronic HCV patients who have LVL at baseline and who
achieve an RVR at 4 weeks of treatment can be treated with
shortened courses of therapy (24weeks for genotype 1; 16weeks
for genotype 2/3) and achieve rates of SVR that are comparable
to those who receive the standard duration of treatment. In ad-
dition, there was a trend for a lower incidence of adverse events
and fewer dose discontinuations in those receiving a shortened
treatment regimen, although some were not tested for statistical
significance. Thus, if patients with specific genotypes meeting
the license criteria receive shortened courses of anti-viral treat-
ment, they may benefit in terms of reduced exposure to adverse
effects which can be unpleasant and may have a considerable
impact on a person’s day to day life, as well as that of family and
carers. However, it is worth noting that some patients may be
willing to tolerate the adverse effects of treatment and prefer to
have the full course of therapy if it may maximize the chance of
achieving an SVR, or reduce the possibility of relapse follow-
ing treatment. Although patients receiving shortened treatment
courses were significantly less likely to relapse compared with
those receiving standard duration treatment, this was only re-
ported in the sub-group of patients with LVL and RVR in one
trial. More data would be needed on relapse rates before there is
any certainty as to whether shortening treatment would not put
patients at higher risk of relapsing at a later date. Furthermore,
it should be noted that SVRs according to baseline LVL and
RVR were based on patient sub-groups as opposed to all ran-
domized patients. It is unlikely that the RCTs were statistically
powered in respect of these sub-groups, so caution is advised in
interpretation of the data.
In the absence of relevant cost-effectiveness papers, a pre-
viously published Markov model was adapted to estimate the
cost-effectiveness of shortened treatment. Shortened duration
of treatment for genotype 1 patients with LVL/RVR, receiv-
ing peginterferon α-2a, reduced total costs by approximately
one third, but resulted in a slightly poorer outcome (QALYs
reduced by approximately 1 percent). The ICERs were positive
(ranging from GBP34,000 to GBP65,000). Because both in-
cremental costs and QALYs are negative, the cost-effectiveness
results should be interpreted in terms of the savings required
for society to accept the reduced outcome (rather than the more
familiar situation in which we are concerned with society’s will-
ingness to pay for a given health gain). In this context, conven-
tional cost-effectiveness thresholds (for example,GBP20,000 or
GBP30,000 per QALY gained in certain contexts (17)) should
be regarded as a minimum, rather than maximum, acceptable
value.
Shorter duration of treatment (from 24 to 16 weeks) with
peginterferon α-2a for genotype 2 and 3 patients reduced total
costs by approximately a quarter, and was associated with a
better outcome in the included trials. In these scenarios, short-
ened treatment duration for the sub-group of genotype 2 or 3
patients with LVL and RVR dominated standard duration ther-
apy. Shorter duration of treatment (from 48 to 24 weeks) with
peginterferon α-2b for the sub-group of genotype 1 patients
with LVL and RVR was associated with a reduction in costs
of approximately GBP9,000. Combined with a QALY gain in-
crease of 0.49, this resulted in peginterferon α-2b dominating
the standard 48 week duration of treatment.
There are some points to take into account when consid-
ering the cost-effectiveness aspect of this review. Some of the
effectiveness data included in our independent model has been
taken from comparatively small trials (20 to 40 patients per arm)
that were not adequately powered to detect differences in SVR,
or were derived from sub-groups of patients in larger trials. In
addition, the proportion of patients with different genotypes in
multi-national clinical trials is unlikely to be reflective of the
genotype distribution in all countries/regions. Hence, the over-
all SVR is unlikely to provide a good indication of response. As
a result, where possible, patient genotypes have been modeled
separately adopting commonly used groupings of “difficult to
treat” genotypes (genotype 1 and occasionally genotype 4) and
more responsive genotypes (2 and 3). However, it is not clear
how closely these distributions, or the assumed mean age of
patients at the start of the model, relate to the characteristics of
patients in the sub-groups of patients covered by this assessment.
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The reported outcomes, in terms of SVR, were inconsistent for
particular genotypes in included trials (with shortened duration
being associated with a lower SVR, than for standard duration,
in two trials (11;27) and a higher SVR in one trial (1) for geno-
type 1 patients) and in some cases appear counter-intuitive (with
a higher SVR for shortened duration compared with standard
treatment in three included trials) (1;25;28). To address the lat-
ter issue, we present a scenario analysis on the impact of the
difference in SVR on the cost-effectiveness results, assuming
that the SVR for shortened treatment duration is less than or
equal to that for standard treatment duration. This suggests that
shortened duration is likely to be a cost-effective option where
the difference in SVR is small and where the cost saving from
shortened treatment duration is greatest (i.e., for genotype 1
patients being treated for 24 rather than 48 weeks).
CONCLUSIONS
In summary, the clinical trial evidence indicates that patients
may be successfully treated with a shorter course of pegin-
terferon alfa and ribavirin combination therapy for 16 weeks
(genotype 2/3), or 24 weeks (genotype 1), without compromis-
ing SVR rates. However, a judgment is required on the value of
the QALY loss that may result from adopting a shorter treatment
regimen, if shorter treatment is associated with a lower SVR
than standard treatment duration. The results from our model
suggest that treatment with peginterferon alfa in the specified
sub-groups of patients with LVL and RVR will yield QALY
gains without excessive increases in costs and may be cost-
saving in some situations. Shortened treatment could therefore
be considered as a viable treatment option for patients and clin-
icians alike. Any future RCTs evaluating shortened treatment
duration should be adequately designed (e.g., randomized at
the point of RVR) and statistically powered to avoid use of
patient subgroups. Relapse rates should be reported and mea-
surement of health-related quality of life would inform future
cost-effectiveness analyses.
POLICY IMPLICATIONS
It is recommended that shortened courses of peginterferon and
ribavirin combination therapy can be prescribed for those pa-
tients who achieve an RVR. When deciding on the duration of
combination therapy, clinicians should take into account the li-
censed indication of the chosen drug (peginterferon alfa-2a or
peginterferon alfa-2b), the genotype of the hepatitis C virus, the
viral load at the start of treatment, and the response to treatment
(as indicated by the viral load).
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